Taofik Nasrat, MD
Neurology · Detroit, MINPI 1275962243
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,299 of the $6,642 with a category attached, or 79.8%. It is spread thinly across 44 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,587 and has fallen 72.0% since, to $725 in 2025.
Across 275 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Alnylam Pharmaceuticals Inc.$544
- Livanova USA, Inc.$511
- Biogen$507
- UCB, Inc.$333
- Novartis$297
- plus $3K from 38 others
Across 2 payments — averaging $17,417 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$35K
What the payments were for
- Travel & lodging$1,33220%
- Food & beverage$5,29980%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$1,114
- VNS - Sentiva$475
- AMVUTTRA$107
How this compares
$6,642 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,949 |
| Lacosamide | 13 | $1,457 |
| Rasagiline Mesylate | 16 | $1,387 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $904 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 52 | $834 |
| Levetiracetam | 31 | $809 |
| Divalproex Sodium | 45 | $596 |
| Duloxetine Hcl | 34 | $545 |
| Gabapentin | 40 | $490 |
| Donepezil Hcl | 70 | $456 |
| Oxcarbazepine | 33 | $426 |
| Memantine Hcl | 14 | $351 |
| Atorvastatin Calcium | 69 | $318 |
| Amitriptyline Hcl | 44 | $304 |
| Ropinirole Hcl | 11 | $188 |
Paid to pharmacies, not to this prescriber.
Other neurology in Detroit
- Bisena BulicaDetroit$900K
- Evanthia BernitsasDetroit$255K
- Andrew RussmanDetroit$118K
- Alex CheblDetroit$68K
- Tobias WalbertDetroit$56K
- Panayiotis VarelasDetroit$48K
- Aaron EllenbogenFarmington Hills$1.6M
- Matthew HoltzmanWayne$1.4M
- Richard TroschFarmington Hills$1.2M
- Wade CooperAnn Arbor$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.